JP7277388B2 - 方法 - Google Patents

方法 Download PDF

Info

Publication number
JP7277388B2
JP7277388B2 JP2019571809A JP2019571809A JP7277388B2 JP 7277388 B2 JP7277388 B2 JP 7277388B2 JP 2019571809 A JP2019571809 A JP 2019571809A JP 2019571809 A JP2019571809 A JP 2019571809A JP 7277388 B2 JP7277388 B2 JP 7277388B2
Authority
JP
Japan
Prior art keywords
cells
cell
antibody
car
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019571809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510704A5 (enExample
JP2020510704A (ja
Inventor
ハロップ，リチャード
Original Assignee
オックスフォード バイオメディカ（ユーケー）リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1704084.1A external-priority patent/GB201704084D0/en
Priority claimed from GBGB1721603.7A external-priority patent/GB201721603D0/en
Application filed by オックスフォード バイオメディカ（ユーケー）リミテッド filed Critical オックスフォード バイオメディカ（ユーケー）リミテッド
Publication of JP2020510704A publication Critical patent/JP2020510704A/ja
Publication of JP2020510704A5 publication Critical patent/JP2020510704A5/ja
Priority to JP2023076631A priority Critical patent/JP2023103318A/ja
Application granted granted Critical
Publication of JP7277388B2 publication Critical patent/JP7277388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019571809A 2017-03-15 2018-03-14 方法 Active JP7277388B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076631A JP2023103318A (ja) 2017-03-15 2023-05-08 方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1704084.1 2017-03-15
GBGB1704084.1A GB201704084D0 (en) 2017-03-15 2017-03-15 Method
GB1721603.7 2017-12-21
GBGB1721603.7A GB201721603D0 (en) 2017-12-21 2017-12-21 Method
PCT/GB2018/050652 WO2018167486A1 (en) 2017-03-15 2018-03-14 Method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076631A Division JP2023103318A (ja) 2017-03-15 2023-05-08 方法

Publications (3)

Publication Number Publication Date
JP2020510704A JP2020510704A (ja) 2020-04-09
JP2020510704A5 JP2020510704A5 (enExample) 2021-04-22
JP7277388B2 true JP7277388B2 (ja) 2023-05-18

Family

ID=61868533

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019571809A Active JP7277388B2 (ja) 2017-03-15 2018-03-14 方法
JP2023076631A Withdrawn JP2023103318A (ja) 2017-03-15 2023-05-08 方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076631A Withdrawn JP2023103318A (ja) 2017-03-15 2023-05-08 方法

Country Status (8)

Country Link
US (2) US11427645B2 (enExample)
EP (1) EP3595705A1 (enExample)
JP (2) JP7277388B2 (enExample)
KR (2) KR20230166145A (enExample)
CN (1) CN110678197A (enExample)
AU (2) AU2018235130B2 (enExample)
CA (1) CA3056542A1 (enExample)
WO (1) WO2018167486A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11126040B2 (en) 2012-09-30 2021-09-21 Optica Amuka (A.A.) Ltd. Electrically-tunable lenses and lens systems
IL269826B1 (en) 2017-04-11 2025-09-01 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20200130723A (ko) 2018-03-12 2020-11-19 젠맵 에이/에스 항체
JP7724061B2 (ja) 2018-04-11 2025-08-15 インヒブルクス バイオサイエンシズ インコーポレイテッド 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
JP7241161B2 (ja) * 2018-08-01 2023-03-16 イミュニティーバイオ、インコーポレイテッド 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム
US20210340273A1 (en) * 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
GB201911958D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of t cell production
US20220325336A1 (en) * 2019-09-05 2022-10-13 Bluebird Bio, Inc. Transduction efficiency assay
CA3152623A1 (en) * 2019-10-11 2021-04-15 Richard D. Cummings Anti-tn antibodies and uses thereof
EP4114449A2 (en) * 2020-03-05 2023-01-11 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
WO2022241151A2 (en) * 2021-05-14 2022-11-17 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
WO2024073522A2 (en) * 2022-09-28 2024-04-04 Sparx Bioscience Limited Antibodies binding to leukocyte immunoglobulin-like receptor subfamily b member 2 (lilrb2) and uses thereof
CN117069849B (zh) * 2023-03-21 2024-02-23 武汉奥科博泰生物科技有限公司 识别nag的单克隆抗体及其应用
CN117074674B (zh) * 2023-03-23 2024-01-23 武汉勖瑞生物科技有限责任公司 检测N-乙酰-β-D氨基葡萄糖苷酶的胶体金试纸及其制备方法
CN119074896A (zh) * 2024-10-11 2024-12-06 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) Il-12在制备治疗t-all的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048369A1 (en) 2009-10-20 2011-04-28 Cancer Research Technology Limited Prognostic, screening and treatment methods and agents for treatment of metastasis and inflammation using t54 oncofoetal glycoprotein
WO2016034666A1 (en) 2014-09-04 2016-03-10 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
WO1989007947A1 (en) 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
WO1992003568A1 (en) 1990-08-13 1992-03-05 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
ATE157100T1 (de) 1993-06-03 1997-09-15 Therapeutic Antibodies Inc Antikoerperfragmente in therapie
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
CN1195863C (zh) 1996-10-17 2005-04-06 牛津生物医学（英国）有限公司 逆转录病毒载体
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
CA2292760A1 (en) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Vector
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
CN1322137C (zh) 1997-12-22 2007-06-20 牛津生物医学（英国）有限公司 基于马传染性贫血病毒(eiav)的逆转录病毒载体
GB2378704B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd Uses of 5t4 antigen
EP1160323A1 (en) 1998-11-18 2001-12-05 Oxford Biomedica (UK) Limited 5T4 tumour-associated antigen for use in tumour immunotherapy
GB9825303D0 (en) * 1998-11-18 1999-01-13 Oxford Biomedica Ltd Vector
GB2370571B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd A modified 5t4 antigen
GB9922361D0 (en) 1999-09-21 1999-11-24 Isis Innovation Generating an immune response to an antigen
EP1242456B1 (en) 1999-11-18 2008-10-15 Oxford Biomedica (UK) Limited Scfv antibodies against disease associated molecules
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
AU2002214150A1 (en) 2000-11-13 2002-05-21 Oxford Biomedica (Uk) Limited Canine and feline tumour-associated antigen 5t4
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
GB0126378D0 (en) 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
EP2348119B1 (en) 2002-02-01 2017-04-26 Oxford BioMedica (UK) Limited Multicistronic lentiviral vector
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
GB0215287D0 (en) * 2002-07-02 2002-08-14 Oxford Biomedica Ltd 5T4 antigen expression
US7662625B2 (en) * 2002-07-02 2010-02-16 Cancer Research Technology Limited Methods for detecting the differentiation status of cells using 5T4 antigen expression
NZ570811A (en) 2002-11-09 2009-11-27 Immunocore Ltd T cell receptor display
EP1786469A2 (en) 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
JP4926168B2 (ja) 2005-05-13 2012-05-09 オックスフォード バイオメディカ（ユーケー）リミテッド ペプチド
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
US8044178B2 (en) * 2006-03-10 2011-10-25 Wyeth Llc Anti-5T4 antibodies and uses thereof
CA2674445C (en) 2007-01-12 2016-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
WO2009070003A2 (en) 2007-11-30 2009-06-04 Mimos Berhad An analog read out interface circuit for ion sensor
EP2433713B1 (en) 2007-12-07 2017-07-26 Miltenyi Biotec GmbH Cell processing systems and methods
WO2010007365A1 (en) 2008-07-15 2010-01-21 Oxford Biomedica (Uk) Ltd Immunotherapeutic method
ES2565439T3 (es) 2009-01-09 2016-04-04 Oxford Biomedica (Uk) Ltd Factores
US8785601B2 (en) 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2010111659A1 (en) * 2009-03-27 2010-09-30 Wyeth Llc Tumor-initiating cells and methods for using same
ES2876176T3 (es) 2010-09-21 2021-11-12 The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso
GB201018480D0 (en) 2010-11-02 2010-12-15 Oxford Biomedica Ltd Factors
SG193324A1 (en) 2011-04-01 2013-10-30 Wyeth Llc Antibody-drug conjugates
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
CN111676196A (zh) 2012-05-25 2020-09-18 塞勒克提斯公司 工程化异体和免疫抑制耐受性t细胞的方法
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
KR102198058B1 (ko) 2012-10-02 2021-01-06 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
WO2015054669A1 (en) * 2013-10-11 2015-04-16 Asana Biosciences, Llc Protein-polymer-drug conjugates
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
US20180161368A1 (en) 2015-05-29 2018-06-14 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
BR112020001180A2 (pt) * 2017-07-20 2020-09-08 Aptevo Research And Development Llc proteínas de ligação a antígenos que se ligam a 5t4 e 4-1bb e composições e métodos relacionados

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048369A1 (en) 2009-10-20 2011-04-28 Cancer Research Technology Limited Prognostic, screening and treatment methods and agents for treatment of metastasis and inflammation using t54 oncofoetal glycoprotein
WO2016034666A1 (en) 2014-09-04 2016-03-10 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Cancer gene therapy, 2002, Vol.9, No.11, pp.884-896，http://dx.doi.org/10.1038/sj.cgt.7700513
CASTRO F V; ET AL，5T4 ONCOFETAL ANTIGEN IS EXPRESSED IN HIGH RISK OF RELAPSE CHILDHOOD PRE-B ACUTE LYMPHOBLASTIC LEUKEMIA AND IS ASSOCIATED WITH A MORE INVASIVE AND CHEMOTACTIC PHENOTYPE，LEUKEMIA，米国，2012年07月，VOL:26, NR:7，PAGE(S):1487 - 1498，http://dx.doi.org/10.1038/leu.2012.18
Clinical Cancer Research, 2016.10.25, Vol.23, No.10, pp.2516-2527，doi: 10.1158/1078-0432.CCR-16-1834
Haematologica, 2017.03.24, Vol.102, No.6, pp.1075-1084
SAPRA P; ET AL，LONG-TERM TUMOR REGRESSION INDUCED BY AN ANTIBODY-DRUG CONJUGATE THAT TARGETS 5T4, AN ONCOFETAL ANTIGEN EXPRESSED ON TUMOR-INITIATING CELLS，MOLECULAR CANCER THERAPEUTICS，2012年12月05日，VOL:12, NR:1，PAGE(S):38 - 47，http://dx.doi.org/10.1158/1535-7163.MCT-12-0603

Also Published As

Publication number Publication date
US11427645B2 (en) 2022-08-30
CN110678197A (zh) 2020-01-10
JP2020510704A (ja) 2020-04-09
AU2023274115A1 (en) 2023-12-21
US20230084645A1 (en) 2023-03-16
JP2023103318A (ja) 2023-07-26
KR102609624B1 (ko) 2023-12-05
AU2018235130A1 (en) 2019-08-29
CA3056542A1 (en) 2018-09-20
AU2018235130B2 (en) 2023-12-07
WO2018167486A1 (en) 2018-09-20
EP3595705A1 (en) 2020-01-22
US20200010560A1 (en) 2020-01-09
KR20230166145A (ko) 2023-12-06
KR20190129861A (ko) 2019-11-20

Similar Documents

Publication Publication Date Title
JP7277388B2 (ja) 方法
RU2729112C2 (ru) Трансгенные генетические метки и способы применения
JP6856188B2 (ja) Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞
JP7433230B2 (ja) 細胞を培養するための無血清培地配合物およびその使用の方法
KR20200071079A (ko) 공동-자극을 위한 신규한 플랫폼, 신규한 car 설계 및 입양 세포 치료를 위한 다른 향상
CN112119157A (zh) 前列腺特异性膜抗原car及其使用方法
KR20200108278A (ko) 조작된 ｔ 세포의 조성물을 제조하는 방법
US20090202544A1 (en) Methods of Treating Diseases by Targeting Silt3
TW201414837A (zh) 標定基質細胞以治療癌症之組合物和方法
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
JP2017522859A (ja) グリピカン３に特異的なｔ細胞受容体、及び肝細胞癌の免疫療法のためのその使用
EP4445912A1 (en) P329g antibody targeting bcma, combination of same with chimeric antigen receptor cell, and use thereof
JP2021512637A (ja) サイクリンａ１特異的ｔ細胞受容体およびその使用
EP4442701A1 (en) Combination of molecular switch regulation type chimeric antigen receptor cell and antibody, and use thereof
KR20240096884A (ko) 조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
IL297916A (en) Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
CN114929341A (zh) 用于治疗髓系恶性肿瘤的嵌合抗原受体
CA3228635A1 (en) Modulation of bcl-2 to enhance chimeric antigen receptor cancer immunotherapy efficacy
KR20230019414A (ko) 항-cd39 항체 및 입양 세포 요법을 포함하는 조합 요법
WO2026003364A1 (en) Chimeric coreceptors
HK40026612A (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230508

R150 Certificate of patent or registration of utility model

Ref document number: 7277388

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150